Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NAMS

NewAmsterdam Pharma Company NV

May 09 • 04:00PM ET

21.86

Dollar change +0.07
Percentage change 0.32	%

Healthcare • Biotechnology • Netherlands • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ONEQ FPXE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	56.03%	Shs Outstand	82.47M	Perf Week	-3.15%
Market Cap	1.95B	Forward P/E	-	EPS next Y	-1.65	Insider Trans	-0.35%	Shs Float	39.25M	Perf Month	14.45%
Income	-	PEG	-	EPS next Q	-0.56	Inst Own	29.28%	Short Float	0.85%	Perf Quarter	11.70%
Sales	-	P/S	-	EPS this Y	-0.16%	Inst Trans	3.27%	Short Ratio	1.53	Perf Half Y	114.31%
Book/sh	5.61	P/B	3.90	EPS next Y	23.15%	ROA	-	Short Interest	0.34M	Perf Year	60.74%
Cash/sh	4.69	P/C	4.66	EPS next 5Y	-	ROE	-	52W Range	5.63 - 26.35	Perf YTD	95.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-820.46%	ROI	-	52W High	-17.04%	Beta	0.07
Dividend TTM	-	Quick Ratio	10.15	Sales past 5Y	-21.57%	Gross Margin	-	52W Low	288.10%	ATR (14)	1.21
Dividend Ex-Date	-	Current Ratio	10.15	EPS Y/Y TTM	-210.57%	Oper. Margin	0.00%	RSI (14)	53.99	Volatility	5.15% 5.80%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	34.71
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-376.21%	Payout	-	Rel Volume	0.41	Prev Close	21.79
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	219.44K	Price	21.86
SMA20	3.88%	SMA50	1.39%	SMA200	50.49%	Trades		Volume	89,951	Change	0.32%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$35
Jan-18-24	Initiated	Guggenheim	Buy	$30
Jan-16-24	Initiated	Piper Sandler	Overweight	$37
Oct-30-23	Initiated	RBC Capital Mkts	Outperform	$25

Today 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-03-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM	NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 (GlobeNewswire)
Apr-09-24 08:00AM	NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Apr-01-24 08:00AM	NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer (GlobeNewswire) -9.64%
08:00AM	Loading…
Mar-25-24 08:00AM	NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress (GlobeNewswire)
Mar-13-24 01:32PM	NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up (Zacks)
Mar-12-24 08:00AM	NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD (GlobeNewswire) +11.89%
Feb-28-24 08:33AM	NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress (GuruFocus.com)
08:00AM	NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-26-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-13-24 10:40PM	NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
04:01PM	NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-01-24 04:01PM	NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 08:00AM	NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors (GlobeNewswire)
08:00AM	Loading…
Jan-04-24 08:00AM	NewAmsterdam Pharma Announces 2024 Strategic Priorities (GlobeNewswire)
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire) -6.91%
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights (GlobeNewswire)
Oct-31-23 12:05PM	RBC initiates coverage of NewAmsterdam on CETP inhibitor (Yahoo Finance Video) +25.52%
Oct-30-23 09:43AM	AbbVie upgraded, Cisco downgraded: Wall Street's top analyst calls (The Fly) +7.01%
Oct-23-23 08:00AM	NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer (GlobeNewswire) -10.07%
Oct-17-23 03:00AM	Tessellate BIO Emerges from Stealth (GlobeNewswire)
Sep-21-23 07:00AM	NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimers Disease Who Carry an ApoE4 Mutation (GlobeNewswire)
Sep-20-23 08:00AM	NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-14-23 04:01PM	NewAmsterdam Pharma Announces Appointment of William BJ Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer (GlobeNewswire)
Aug-10-23 06:01AM	NewAmsterdam Pharma First Half 2023 Earnings: 0.92 loss per share (vs 1.50 profit in 1H 2022) (Simply Wall St.)
Aug-07-23 07:15AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights (GlobeNewswire)
Jul-25-23 04:01PM	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Jun-09-23 04:01PM	NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares (GlobeNewswire)
Jun-06-23 11:25PM	NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares (GlobeNewswire)
04:01PM	Loading…
04:01PM	NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares (GlobeNewswire)
Jun-05-23 07:00AM	NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients (GlobeNewswire)
Jun-03-23 12:15PM	NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 (GlobeNewswire)
May-31-23 08:00AM	NewAmsterdam Pharma to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 08:00AM	NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023 (GlobeNewswire)
May-08-23 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights (GlobeNewswire)

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Topper James N	Director	Mar 26 '24	Buy	21.50	8,429	181,224	3,008,429	Mar 28 04:30 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 26 '24	Sale	21.50	190,476	4,095,234	0	Mar 27 04:30 PM
LANGE LOUIS G	Director	Feb 13 '24	Buy	19.00	5,000	95,000	24,878	Feb 21 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NAMS

NewAmsterdam Pharma Company NV

Upgrade your FINVIZ experience